Products
Nemolizumab Biosimilar Monoclonal Antibody (IL-31RA) for Research
Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-372-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody |
| INN Name | Nemolizumab |
| Target | IL31R |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Chugai Pharmaceutical;Galderma;Maruho |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis;Prurigo nodularis;Pruritus |
| Conditions Discontinued | na |
| Development Tech | na |
About target - IL31RA
1. Protein Interleukin-31 receptor subunit alpha
2. Gene IL31RA
3. Organism Homo sapiens (Human)
Function
Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5 (PubMed:11877449, PubMed:14504285, PubMed:15627637, PubMed:15194700).
May function in skin immunity (PubMed:15184896).
Mediates IL31-induced itch, probably in a manner dependent on cation channels TRPA1 and TRPV1 (By similarity).
Positively regulates numbers and cycling status of immature subsets of myeloid progenitor cells in bone marrow in vivo and enhances myeloid progenitor cell survival in vitro (By similarity).
